Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zactima · 2 trials · 4 indications
Prostate Specific Antigen (PSA) response was defined as a reduction of at least 50% from baseline at any assessment, confirmed by a second assessment 2-4 weeks after the initial response
| Name | Type | Description |
|---|---|---|
| Zactima (vandetanib) | DRUG | - |
| Docetaxel | DRUG | - |
| Prednisolone | DRUG | - |
| Zactima (ZD6474) | DRUG | - |
| Vinorelbine plus cisplatin | DRUG | - |
| Gemcitabine plus cisplatin | DRUG | - |
Inclusion Criteria: * Metastatic hormone refractory prostate cancer defined as those patients with evidence of progression of disease in spite of castrate levels of testosterone indicated by rising levels of PSA * No previous chemotherapy although those patients that have received estramustine can ...
Top 20 of 53 competitors
Zactima is an investigational small molecule being developed for oncology indications, specifically non-small cell lung cancer and prostate cancer. It has been studied in clinical trials for these conditions, including a Phase 1 trial in locally advanced or metastatic non-small cell lung cancer and a Phase 2 trial in metastatic hormone-refractory prostate cancer.
Zactima is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is responsible for the clinical development of this investigational oncology drug.
Zactima is in clinical development, with completed trials including a Phase 1 study and a Phase 2 study. The drug is investigational and has not been approved by regulatory authorities. Its development status is based on the completed clinical trials for non-small cell lung cancer and prostate cancer.
Zactima has been studied in two completed clinical trials. NCT00496275 was a Phase 1 combination trial with vinorelbine or gemcitabine plus cisplatin in locally advanced or metastatic non-small cell lung cancer, enrolling 17 participants. NCT00498797 was a Phase 2 trial combining Zactima with Taxotere in metastatic hormone-refractory prostate cancer, enrolling 86 participants.
Zactima is a small molecule therapeutic agent. Its specific molecular target has not been disclosed in the available information, so its mechanism of action is not detailed here. It is being investigated for its potential role in treating non-small cell lung cancer and prostate cancer.